Carl E. Freter, MD, PhD, FACP is the Director of the Division of Hematology and Oncology at Saint Louis University. He is a tenured Professor of Medicine, Interim Director of the Saint Louis University Cancer Center and the Rosalie Fusz Endowed Chair of Hematology. Dr. Freter is also the Director of the Fellowship Program in Hematology and Oncology.
Dr. Freter received his MD and PhD in biochemistry at Washington University School of Medicine. He did his internship and residency training at Stanford University, and his fellowship in hematology/oncology at the National Cancer Institute at the NIH. Before coming to Saint Louis University in 2014, Dr. Freter was the Co-Director of the Ellis Fischel Cancer Center at the University of Missouri-Columbia, as well as the Director of the Division of Hematology and Oncology and the Fellowship Program in Hematology and Oncology.
He is one of America’s Top Oncologists and for the last 4 years, been featured in St. Louis Magazine’s Annual Best Doctors of St. Louis issue. He is a member of the American College of Physicians, American Association of Cancer Research, American Society of Clinical Oncology, and American Society of Hematology. In 2014, Dr. Freter was honored at the annual Leukemia/Lymphoma Meeting in St. Louis for assistance in testimony in the passing or the oral chemotherapy parity bill in the state of Missouri.
Dr. Freter’s areas of expertise in both clinical and research areas include breast cancer, malignant hematology, leukemia and lymphoma. He has two research laboratories at Saint Louis University engaged in anti-cancer research. Dr. Freter is the President and CEO of his own biotech start-up company, ONCOLYSIS, LLP.
He has authored multiple book chapters and articles in peer reviewed journals. He has presented at many international and national conferences and has participated in NIH and industry sponsored research projects. Dr. Freter has received NIH funding on multiple research projects and funding from multiple other outside sources for conducting cancer research.